New Hope for Sleep Apnea Sufferers
Those dealing with sleep apnea might soon have a new way to improve their sleep quality. A biotech startup from Massachusetts is gearing up to seek FDA approval for a nighttime pill that could mark the first medication sanctioned for treating obstructive sleep apnea (OSA).
Sleep apnea affects about 30 million adults across the United States. This condition is characterized by interrupted breathing throughout the night, leaving many feeling far from rested when morning arrives.
Understanding Sleep Apnea
There are primarily two forms of sleep apnea: obstructive sleep apnea (OSA) and central sleep apnea. As outlined by the National Institutes of Health (NIH), OSA generally occurs when something physically blocks the airway, leading to breathing pauses.
On the other hand, central sleep apnea arises when the brain fails to send appropriate signals to breathe, sometimes due to other health issues.
“Individuals with OSA often experience brief awakenings as their breathing periodically halts,” explained Dr. Paul Muchowski, a sleep expert based in San Francisco. “These interruptions can upset normal sleep cycles and, over time, diminish the quality of restorative sleep.”
People with this condition often wake feeling fatigued and irritable. Their struggles can include difficulties with focus, memory issues, and sometimes headaches. Moreover, long-term OSA can heighten risks for heart disease and neurodegenerative disorders like Alzheimer’s and Parkinson’s.
The Cleveland Clinic notes that diagnosing sleep apnea involves sleep studies that track various body functions, assessing overall sleep quality. Surprisingly, many individuals remain unaware that they have this condition.
Current Treatment Options
The go-to treatment for OSA is the use of a continuous positive airway pressure (CPAP) machine, which keeps airways open during sleep via a mask. However, many find CPAP machines uncomfortable, which can dissuade people from seeking help even after receiving a diagnosis.
In 2024, the FDA approved a weight loss medication called Zepbound for managing moderate to severe OSA but limited its use to adults with obesity who had not seen improvements with diet and exercise alone. However, this drug does not address the root cause of OSA and merely facilitates weight loss.
In more invasive scenarios, options like surgery to remove enlarged tonsils may be considered.
Pill Development by ApniMed
ApniMed, a pharmaceutical company based in Cambridge, Massachusetts, has created AD109, a potential medication aimed at individuals who can’t tolerate CPAP devices. Currently, there are no FDA-approved oral medications specifically designated for obstructive sleep apnea.
Dr. Muchowski described the development of a sleep apnea medication as a “long-sought holy grail” for researchers. The drug is believed to assist in keeping airways open during sleep by addressing the dysfunction between the brain and throat muscles.
AD109 combines two medications: Alloxybutynin and atomoxetine, which together aim to improve nighttime breathing. In a Phase 3 clinical trial, participants taking the drug experienced a notable reduction in breathing interruptions—on average, they saw a 55.6% decrease in nocturnal apnea over 26 weeks. Furthermore, improvements in oxygenation were also reported.
While some participants experienced mild side effects like dry mouth and insomnia, there were no serious adverse effects tied to AD109.
Dr. Muchowski remarked that the data backing AD109 as a treatment is quite compelling. Should it receive FDA approval, it could potentially help millions worldwide sleep better and escape the harmful repercussions of OSA.
ApniMed aims to submit its new drug application to the FDA in early 2026. The review process can take about 10 months, which might allow for the pill to be available by early 2027. The company has stressed the importance of conducting this process diligently.
